JP6120392B2 - 組織接着性多孔質膜、その製造方法及び組織接着性多孔質膜テープ - Google Patents
組織接着性多孔質膜、その製造方法及び組織接着性多孔質膜テープ Download PDFInfo
- Publication number
- JP6120392B2 JP6120392B2 JP2015549152A JP2015549152A JP6120392B2 JP 6120392 B2 JP6120392 B2 JP 6120392B2 JP 2015549152 A JP2015549152 A JP 2015549152A JP 2015549152 A JP2015549152 A JP 2015549152A JP 6120392 B2 JP6120392 B2 JP 6120392B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- tissue
- gelatin
- porous membrane
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000012528 membrane Substances 0.000 title claims description 288
- 239000003106 tissue adhesive Substances 0.000 title claims description 249
- 238000004519 manufacturing process Methods 0.000 title claims description 38
- 108010010803 Gelatin Proteins 0.000 claims description 252
- 229920000159 gelatin Polymers 0.000 claims description 252
- 235000019322 gelatine Nutrition 0.000 claims description 252
- 235000011852 gelatine desserts Nutrition 0.000 claims description 252
- 239000008273 gelatin Substances 0.000 claims description 243
- 239000003361 porogen Substances 0.000 claims description 111
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 102
- 230000002209 hydrophobic effect Effects 0.000 claims description 91
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 89
- 229910052799 carbon Inorganic materials 0.000 claims description 89
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 87
- 125000004432 carbon atom Chemical group C* 0.000 claims description 69
- -1 tridecanoyl Group Chemical group 0.000 claims description 69
- 239000003960 organic solvent Substances 0.000 claims description 63
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 57
- 239000002245 particle Substances 0.000 claims description 57
- 239000011780 sodium chloride Substances 0.000 claims description 51
- 125000000524 functional group Chemical group 0.000 claims description 39
- 239000011148 porous material Substances 0.000 claims description 36
- 230000001070 adhesive effect Effects 0.000 claims description 32
- 239000000853 adhesive Substances 0.000 claims description 31
- 239000003795 chemical substances by application Substances 0.000 claims description 26
- 239000003431 cross linking reagent Substances 0.000 claims description 24
- 125000003277 amino group Chemical group 0.000 claims description 23
- 238000004132 cross linking Methods 0.000 claims description 21
- QMIHEVHZZOEHCB-UHFFFAOYSA-N tris(2,5-dioxopyrrolidin-1-yl) 2-hydroxypropane-1,2,3-tricarboxylate Chemical group O=C1CCC(=O)N1OC(=O)CC(C(=O)ON1C(CCC1=O)=O)(O)CC(=O)ON1C(=O)CCC1=O QMIHEVHZZOEHCB-UHFFFAOYSA-N 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 15
- 239000003112 inhibitor Substances 0.000 claims description 13
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 12
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 229940088598 enzyme Drugs 0.000 claims description 7
- 239000003527 fibrinolytic agent Substances 0.000 claims description 7
- 239000003018 immunosuppressive agent Substances 0.000 claims description 7
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- 150000001721 carbon Chemical class 0.000 claims description 6
- 210000000170 cell membrane Anatomy 0.000 claims description 6
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 claims description 6
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 5
- 241000282414 Homo sapiens Species 0.000 claims description 5
- 150000001718 carbodiimides Chemical class 0.000 claims description 5
- 239000002738 chelating agent Substances 0.000 claims description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 5
- 210000002744 extracellular matrix Anatomy 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- AOBIOSPNXBMOAT-UHFFFAOYSA-N 2-[2-(oxiran-2-ylmethoxy)ethoxymethyl]oxirane Chemical compound C1OC1COCCOCC1CO1 AOBIOSPNXBMOAT-UHFFFAOYSA-N 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 229940123457 Free radical scavenger Drugs 0.000 claims description 4
- AZKVWQKMDGGDSV-BCMRRPTOSA-N Genipin Chemical compound COC(=O)C1=CO[C@@H](O)[C@@H]2C(CO)=CC[C@H]12 AZKVWQKMDGGDSV-BCMRRPTOSA-N 0.000 claims description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 4
- 229940122853 Growth hormone antagonist Drugs 0.000 claims description 4
- 102000012750 Membrane Glycoproteins Human genes 0.000 claims description 4
- 108010090054 Membrane Glycoproteins Proteins 0.000 claims description 4
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 claims description 4
- 229940122388 Thrombin inhibitor Drugs 0.000 claims description 4
- 241000276707 Tilapia Species 0.000 claims description 4
- 206010047163 Vasospasm Diseases 0.000 claims description 4
- 231100000764 actin inhibitor Toxicity 0.000 claims description 4
- 230000001093 anti-cancer Effects 0.000 claims description 4
- 230000000340 anti-metabolite Effects 0.000 claims description 4
- 230000001028 anti-proliverative effect Effects 0.000 claims description 4
- 230000000692 anti-sense effect Effects 0.000 claims description 4
- 239000003146 anticoagulant agent Substances 0.000 claims description 4
- 229940100197 antimetabolite Drugs 0.000 claims description 4
- 239000002256 antimetabolite Substances 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 229940127218 antiplatelet drug Drugs 0.000 claims description 4
- 229960004676 antithrombotic agent Drugs 0.000 claims description 4
- NXVYSVARUKNFNF-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) 2,3-dihydroxybutanedioate Chemical compound O=C1CCC(=O)N1OC(=O)C(O)C(O)C(=O)ON1C(=O)CCC1=O NXVYSVARUKNFNF-UHFFFAOYSA-N 0.000 claims description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 239000000480 calcium channel blocker Substances 0.000 claims description 4
- 230000024245 cell differentiation Effects 0.000 claims description 4
- 230000010261 cell growth Effects 0.000 claims description 4
- 239000000306 component Substances 0.000 claims description 4
- 239000000824 cytostatic agent Substances 0.000 claims description 4
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims description 4
- 238000001415 gene therapy Methods 0.000 claims description 4
- AZKVWQKMDGGDSV-UHFFFAOYSA-N genipin Natural products COC(=O)C1=COC(O)C2C(CO)=CCC12 AZKVWQKMDGGDSV-UHFFFAOYSA-N 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 125000000268 heptanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 230000001861 immunosuppressant effect Effects 0.000 claims description 4
- 239000000411 inducer Substances 0.000 claims description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000005644 linolenyl group Chemical group 0.000 claims description 4
- 229940049920 malate Drugs 0.000 claims description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 4
- 125000000628 margaroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims description 4
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 4
- 125000001402 nonanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 claims description 4
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 239000002516 radical scavenger Substances 0.000 claims description 4
- 108091006082 receptor inhibitors Proteins 0.000 claims description 4
- 238000007634 remodeling Methods 0.000 claims description 4
- 239000003868 thrombin inhibitor Substances 0.000 claims description 4
- 125000000297 undecanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 4
- 229940124549 vasodilator Drugs 0.000 claims description 4
- 239000003071 vasodilator agent Substances 0.000 claims description 4
- 229940122937 Actin inhibitor Drugs 0.000 claims description 3
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 3
- 230000001262 anti-secretory effect Effects 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- ZSNFGVQUPMRCIP-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) butanedioate Chemical compound O=C1CCC(=O)N1OC(=O)CCC(=O)ON1C(=O)CCC1=O ZSNFGVQUPMRCIP-UHFFFAOYSA-N 0.000 claims description 3
- 230000001085 cytostatic effect Effects 0.000 claims description 3
- 229940052760 dopamine agonists Drugs 0.000 claims description 3
- 231100000782 microtubule inhibitor Toxicity 0.000 claims description 3
- 238000002428 photodynamic therapy Methods 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 229960000103 thrombolytic agent Drugs 0.000 claims description 3
- 229940122255 Microtubule inhibitor Drugs 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 claims description 2
- 230000003276 anti-hypertensive effect Effects 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 229940044683 chemotherapy drug Drugs 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims 1
- 230000003439 radiotherapeutic effect Effects 0.000 claims 1
- 229910052711 selenium Inorganic materials 0.000 claims 1
- 239000011669 selenium Substances 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 63
- 239000000243 solution Substances 0.000 description 56
- 230000000052 comparative effect Effects 0.000 description 43
- 239000003513 alkali Substances 0.000 description 24
- 239000000047 product Substances 0.000 description 22
- 238000000635 electron micrograph Methods 0.000 description 21
- 210000002615 epidermis Anatomy 0.000 description 17
- 210000002429 large intestine Anatomy 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 238000010521 absorption reaction Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 229910021642 ultra pure water Inorganic materials 0.000 description 11
- 239000012498 ultrapure water Substances 0.000 description 11
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000000523 sample Substances 0.000 description 8
- 239000006227 byproduct Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 229940075469 tissue adhesives Drugs 0.000 description 6
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 239000004310 lactic acid Substances 0.000 description 5
- 235000014655 lactic acid Nutrition 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 229920001296 polysiloxane Polymers 0.000 description 5
- 230000017423 tissue regeneration Effects 0.000 description 5
- 239000004830 Super Glue Substances 0.000 description 4
- 238000004873 anchoring Methods 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- FGBJXOREULPLGL-UHFFFAOYSA-N ethyl cyanoacrylate Chemical compound CCOC(=O)C(=C)C#N FGBJXOREULPLGL-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- YWGHUJQYGPDNKT-UHFFFAOYSA-N hexanoyl chloride Chemical compound CCCCCC(Cl)=O YWGHUJQYGPDNKT-UHFFFAOYSA-N 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 241000276438 Gadus morhua Species 0.000 description 3
- 208000031737 Tissue Adhesions Diseases 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000009864 tensile test Methods 0.000 description 3
- 239000011800 void material Substances 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 2
- 208000023514 Barrett esophagus Diseases 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 235000003441 saturated fatty acids Nutrition 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- IFABLCIRROMTAN-MDZDMXLPSA-N (e)-1-chlorooctadec-9-ene Chemical compound CCCCCCCC\C=C\CCCCCCCCCl IFABLCIRROMTAN-MDZDMXLPSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 238000013130 cardiovascular surgery Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Substances ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- IPIVAXLHTVNRBS-UHFFFAOYSA-N decanoyl chloride Chemical compound CCCCCCCCCC(Cl)=O IPIVAXLHTVNRBS-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 238000007038 hydrochlorination reaction Methods 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 1
- 230000006855 networking Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- WTBAHSZERDXKKZ-UHFFFAOYSA-N octadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCCCC(Cl)=O WTBAHSZERDXKKZ-UHFFFAOYSA-N 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- VSIVTUIKYVGDCX-UHFFFAOYSA-M sodium;4-[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].COC1=CC([N+]([O-])=O)=CC=C1[N+]1=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 VSIVTUIKYVGDCX-UHFFFAOYSA-M 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000002731 stomach secretion inhibitor Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0036—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/104—Gelatin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Surgery (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Pharmacology & Pharmacy (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013241764 | 2013-11-22 | ||
| JP2013241764 | 2013-11-22 | ||
| PCT/JP2014/080477 WO2015076252A1 (fr) | 2013-11-22 | 2014-11-18 | Film poreux adhésif tissulaire, son procédé de fabrication, et bande de film poreux adhésif tissulaire |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2015076252A1 JPWO2015076252A1 (ja) | 2017-03-16 |
| JP6120392B2 true JP6120392B2 (ja) | 2017-04-26 |
Family
ID=53179514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015549152A Expired - Fee Related JP6120392B2 (ja) | 2013-11-22 | 2014-11-18 | 組織接着性多孔質膜、その製造方法及び組織接着性多孔質膜テープ |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP6120392B2 (fr) |
| WO (1) | WO2015076252A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3248622B1 (fr) * | 2015-01-20 | 2020-08-19 | National Institute for Materials Science | Agent d'étanchéité chirurgical |
| US11679177B2 (en) | 2017-08-08 | 2023-06-20 | Baxter International Inc. | Polymeric compositions, delivery devices, and methods |
| JP6854740B2 (ja) * | 2017-10-27 | 2021-04-07 | 株式会社豊田中央研究所 | 多孔質細胞足場及びその利用 |
| JP7127888B2 (ja) * | 2018-09-05 | 2022-08-30 | 国立研究開発法人物質・材料研究機構 | 癒着防止材 |
| EP3862016B1 (fr) * | 2018-10-04 | 2024-04-24 | National Institute for Materials Science | Promoteur d'angiogenèse pour l'utilisation dans le traitement des maladies artérielles périphériques |
| CN111298192B (zh) * | 2020-03-06 | 2021-11-16 | 华中科技大学同济医学院附属协和医院 | 一种用于皮肤和黏膜破损部位的防护性修复水凝胶及其制备方法 |
| WO2024053602A1 (fr) * | 2022-09-06 | 2024-03-14 | 国立研究開発法人物質・材料研究機構 | Feuille poreuse, film adhésif tissulaire, leur utilisation en tant qu'agent hémostatique ou matériau anti-adhérence, et leurs procédés de production |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004018163D1 (de) * | 2003-08-29 | 2009-01-15 | Mayo Foundation | Hydrogel-porenbildner zur herstellung von biologisch abbaubaren gerüsten |
| EP2626087B1 (fr) * | 2010-10-05 | 2016-08-17 | National Institute for Materials Science | Film d'adhésif tissulaire et procédé de production de celui-ci |
| JP2014005211A (ja) * | 2012-06-21 | 2014-01-16 | Kagoshima Univ | ゼラチンゲルの作製法 |
| JP6048811B2 (ja) * | 2012-11-22 | 2016-12-21 | 国立研究開発法人物質・材料研究機構 | 組織接着膜及びその製造方法 |
-
2014
- 2014-11-18 WO PCT/JP2014/080477 patent/WO2015076252A1/fr active Application Filing
- 2014-11-18 JP JP2015549152A patent/JP6120392B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2015076252A1 (ja) | 2017-03-16 |
| WO2015076252A1 (fr) | 2015-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6120392B2 (ja) | 組織接着性多孔質膜、その製造方法及び組織接着性多孔質膜テープ | |
| EP3204057B1 (fr) | Produit hémostatique poreux adhérant aux tissus | |
| EP2600910B1 (fr) | Pansements et adhésifs contenant des compositions sèches | |
| JP6042815B2 (ja) | 生物医学的応用のためのアルギン酸塩及びヒアルロン酸を用いる抗癒着性バリア膜 | |
| TWI436793B (zh) | 快速作用之乾密封膠及其使用和製造方法 | |
| DK2442835T3 (en) | Styptic sponge | |
| Nishiguchi et al. | Multifunctional hydrophobized microparticles for accelerated wound healing after endoscopic submucosal dissection | |
| JP6446031B2 (ja) | フィブリノーゲンをベースとする組織接着性パッチ剤 | |
| JP2017153975A (ja) | 止血組成物 | |
| JP7143222B2 (ja) | メッシュベースのインサイチュ架橋性組成物 | |
| WO2012046717A1 (fr) | Adhésif tissulaire à deux composants et procédé de production de celui-ci | |
| NL2016524B1 (en) | Tissue-adhesive material | |
| EP2707042B1 (fr) | Scellements tissulaires dérivés de protéines dérivées de plasma | |
| JP5747264B2 (ja) | 組織接着膜及びその製造方法 | |
| US20220111112A1 (en) | Flexible Gelatin Sealant Dressing with Reactive Components | |
| GB2561947A (en) | Tissue-adhesive materials | |
| JP6048811B2 (ja) | 組織接着膜及びその製造方法 | |
| WO2024000861A1 (fr) | Maillage biologique absorbable auto-adhésif à deux composants peg, son procédé de préparation et utilisation associée | |
| CN114848668B (zh) | 具有促进伤口愈合和快速止血功能的组合物 | |
| KR101865160B1 (ko) | 조직 접착용 시트 제제 | |
| Ghavamzadeh et al. | Bioadhesion and biocompatibility evaluations of gelatin and polyacrylic acid as a crosslinked hydrogel in vitro | |
| WO2022023375A1 (fr) | Feuille adhésive osseuse |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161220 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170118 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20170118 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170213 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170307 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170323 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6120392 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |